GlassScriptPhysician profile
Gregory S Gelburd
NPI 1417994146
$1,548.47
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $229 · 2021: $505 · 2022: $314.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $395.50 | 2019-2022 | |
| Pfizer INC. | $230.43 | 2019-2022 | |
| Lilly USA, LLC | $152.04 | 2019-2021 | |
| Novo Nordisk INC | $87.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $85.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $68.73 | 2019-2021 | |
| Abbvie INC. | $66.85 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $64.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.26 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $44.78 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.01 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.05 | 2022 | |
| Genentech USA, INC. | $33.27 | 2019 | |
| Sanofi Pasteur INC. | $30.10 | 2021-2022 | |
| Bausch Health US, LLC | $26.35 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.79 | 2019-2020 | |
| Abbott Laboratories | $23.66 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.58 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.53 | 2019 | |
| Shire North American Group INC | $15.71 | 2019 | |
| Amarin Pharma, INC. | $15.53 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gelburd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.